You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial

The phase 3 trials will assess Epidiolex over 14 weeks in a randomised, double-blind, placebo-controlled study, enrolling paediatric patients aged one to 18.